AdvaTx
Device Facts
| Record ID | K250189 |
|---|---|
| Device Name | AdvaTx |
| Applicant | Advalight Aps |
| Product Code | GEX · General, Plastic Surgery |
| Decision Date | Apr 1, 2025 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 878.4810 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Intended Use
The ADVATx at 589 nm is indicated for use for dermatologic treatment of benign cutaneous vascular lesions including but not limited to: treatment of wrinkles, periocular wrinkles, periorbital wrinkles, facial and leg telangiectasia, rosacea. cherry angiomas, port wine stains, hemangiomas and venous lakes, angioma, spider angioma, Poikiloderma of Civatte, inflammatory acne vulgaris, verrucae/ warts, scars, striae, psoriasis and the treatment of benign pigmented lesions. The ADVATx at 1319 nm is indicated for treatment of fine lines and wrinkles. Treatment of atrophic acne scars. Treatment of mild and moderate inflammatory acne vulgaris.
Device Story
AdvaTx is a non-ablative laser system utilizing 589 nm and 1319 nm wavelengths for dermatologic procedures. The device comprises a console, a handpiece with an integrated scanner and distance guide, and a trigger mechanism. It operates on the principle of selective photothermolysis, delivering controlled light pulses to specific chromophores in epidermal and dermal tissue to induce thermal damage. Used in clinical settings by healthcare professionals, the device allows for precise energy delivery to treat vascular and pigmented lesions, acne, and skin texture concerns. The provider uses the handpiece to target specific areas; the resulting thermal effect facilitates tissue remodeling or lesion coagulation. Benefits include non-invasive treatment of various cutaneous conditions with adjustable fluence and pulse parameters.
Clinical Evidence
No clinical studies were conducted. Substantial equivalence is supported by bench testing, including electrical safety, electromagnetic compatibility, laser safety, and biocompatibility (ISO 10993-1), alongside software verification and validation.
Technological Characteristics
Non-ablative laser system; dual wavelengths (589 nm, 1319 nm). Fluence: up to 100 J/cm² (589 nm) and 60 J/cm² (1319 nm). Pulse width: 20-950 ms (589 nm), 20-200 ms (1319 nm). Repetition rate: 0.67-1.0 Hz. Features a console, handpiece with scanner, and distance guide. Power: 110-240 V, 50/60 Hz. Standards: IEC 60601-1, IEC 60601-1-2, IEC 60601-2-22, ISO 10993-1.
Indications for Use
Indicated for dermatologic treatment of benign cutaneous vascular lesions (e.g., telangiectasia, rosacea, port wine stains, hemangiomas, angiomas, venous lakes, Poikiloderma of Civatte), benign pigmented lesions, inflammatory acne vulgaris, atrophic acne scars, warts, scars, striae, psoriasis, and wrinkles (including periocular/periorbital/fine lines) in patients requiring dermatologic laser therapy.
Regulatory Classification
Identification
(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
Predicate Devices
- AdvaTX (K132976)
Reference Devices
Related Devices
- K132976 — ADVATX · Advalight Aps · Apr 17, 2014
- K251464 — TRI-BEAM PRO, TRI-BEAM (Nd:YAG Laser unit) · Jeisys Medical Incorporated · Oct 3, 2025
- K050673 — CANDELA FAMILY OF PULSE DYE LASER SYSTEMS · Candela Corp. · Jun 13, 2005
- K033461 — CANDELA VBEAM PULSE DYE LASER SYSTEM · Candela Corp. · Jan 16, 2004
- K034030 — APOGEE ELITE · Cynosure, Inc. · Feb 9, 2004
Submission Summary (Full Text)
{0}
FDA U.S. FOOD & DRUG ADMINISTRATION
April 1, 2025
AdvaLight APS
Amogh Kothare
Chief Scientific Officer
Industriparken 22A
Bellerup Hovedstaden, DK DK-2750
Denmark
Re: K250189
Trade/Device Name: AdvaTx
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser Surgical Instrument For Use In General And Plastic Surgery And In Dermatology
Regulatory Class: Class II
Product Code: GEX
Dated: January 22, 2025
Received: January 22, 2025
Dear Amogh Kothare:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov
{1}
K250189 - Amogh Kothare
Page 2
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
{2}
K250189 - Amogh Kothare
Page 3
Sincerely,
YAN FU -S
Digitally signed by YAN FU -S
Date: 2025.04.01 15:01:47
-04'00'
for Tanisha Hithe
Assistant Director
DHT4A: Division of General Surgery Devices
OHT4: Office of Surgical and
Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Enclosure
{3}
FORM FDA 3881 (8/14)
Page 1 of 1
PSC Publishing Services (301) 443-6740
EF
| DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use | Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below. |
| --- | --- |
| 510(k) Number (if known) K250189 | |
| Device Name AdvaTx | |
| Indications for Use (Describe) The ADVATx at 589 nm is indicated for use for dermatologic treatment of benign cutaneous vascular lesions including but not limited to: treatment of wrinkles, periocular wrinkles, periorbital wrinkles, facial and leg telangiectasia, rosacea. cherry angiomas, port wine stains, hemangiomas and venous lakes, angioma, spider angioma, Poikiloderma of Civatte, inflammatory acne vulgaris, verrucae/ warts, scars, striae, psoriasis and the treatment of benign pigmented lesions. The ADV ATx at 1319 nm is indicated for treatment of fine lines and wrinkles. Treatment of atrophic acne scars. Treatment of mild and moderate inflammatory acne vulgaris. | |
| Type of Use (Select one or both, as applicable) ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | |
| CONTINUE ON A SEPARATE PAGE IF NEEDED. | |
| This section applies only to requirements of the Paperwork Reduction Act of 1995. *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* | |
| The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." | |
{4}
510(k) Summary for AdvaTx K250189
A summary of 510(k) safety and effectiveness information in accordance with the requirements of 21 CFR 807.92
I. Submitter Information [21 CFR 807.92(a) (1)]
| Owner Name | AdvaLight APS |
| --- | --- |
| Address | Industriparken 22A
Bellerup
Denmark DK-2750 |
| Contact Person | Amogh Kothare
Chief Scientific Officer
Adk@advalight.com
415-690-6796 |
| Summary Preparation Date | February 20, 2024 |
II. Name of device [21 CFR 807.92 (a) (2)]
| Device Name | Common Device Name(s) and Regulatory Class | Product Code(s) | Classification Panel | Regulation |
| --- | --- | --- | --- | --- |
| AdvaTX | Laser Surgical Instrument for use in general and plastic surgery and in dermatology Class II | GEX | General & Plastic Surgery Panel | § 21 CFR 878.4810 |
III. Intended use of device and Indications for Use [21 CFR 807.92(a) (5)]
The ADVATx at 589 nm is indicated for use for dermatologic treatment of benign cutaneous vascular lesions including but not limited to: treatment of wrinkles, periocular wrinkles, periorbital wrinkles, facial and leg telangiectasia, rosacea. cherry angiomas, port wine stains, hemangiomas and venous lakes, angioma, spider angioma, Poikiloderma of Civatte, inflammatory acne vulgaris, verrucae/ warts, scars, striae, psoriasis and the treatment of benign pigmented lesions.
The ADVATx at 1319 nm is indicated for treatment of fine lines and wrinkles. Treatment of atrophic acne scars. Treatment of mild and moderate inflammatory acne vulgaris.
IV. Device Description [21 CFR 807.92(a) (4)]
The AdvaTx is non-ablative laser with two wavelengths: 1319nm and 589nm. There are multiple indications for use that are specific to each wavelength. The AdvaTx consists of a console, a handpiece that has a scanner and a distance guide. The laser is activated using a trigger that is located on the handpiece.
{5}
510(k) Summary for AdvaTx K250189
The AdvaTx produces light pulses with a specific duration, intensity, and spectral distribution allowing for a controlled and confined energy delivery into tissue. Laser use in dermatology relies on the basis that certain targets for energy absorption (chromophores) are capable of absorbing energy from the specific light wavelength (absorptive band) without exclusively being targeted by their highest absorption peak. The working basis of the laser rests on the principle of selective photothermolysis, in which thermally mediated radiation damage is confined to chosen epidermal and/or dermal pigmented targets at the cellular or tissue structural levels
# V. Summary of technological characteristics of the device compared to the predicate [21 CFR 807.92(a)(6)]
The subject device and the predicate device share the same technical characteristics with one exception. The fluence for the 1319nm laser is increased to $60\mathrm{J} / \mathrm{cm}^2$ . This is the same fluence as the reference device.
This submission has one predicate device and two reference devices as stated in the table below.
| Predicate K Number | Predicate / Reference Name |
| --- | --- |
| K132976 | AdvaTX |
| K033176 | Cynocure TriStar Aesthetic Workstation |
| K043251 | Candela VBeam |
{6}
510(k) Summary for AdvaTx K250189
Indication for Use and Technical Characteristics Comparison Table
| | AdvaTx (Subject Device) | AdvaTx K132976 (Predicate Device) | VBeam (Reference Device) | TriStar (Reference Device) | Comparison |
| --- | --- | --- | --- | --- | --- |
| | The ADVATx at 589 nm is indicated for use for dermatologic treatment of benign cutaneous vascular lesions including but not limited to: treatment of wrinkles, periocular wrinkles, periorbital wrinkles, facial and leg telangiectasia, rosacea. cherry angiomas, port wine stains, hemangiomas and venous lakes, angioma, spider angioma, Poikiloderma of Civatte, inflammatory acne vulgaris, verrucae/ warts, scars, striae, psoriasis and | The ADVATx at 589 nm is indicated for use for dermatologic treatment of benign cutaneous vascular lesions including but not limited to: treatment of wrinkles, periocular wrinkles, periorbital wrinkles, facial and leg telangiectasia, rosacea. cherry angiomas, port wine stains, hemangiomas and venous lakes, angioma, spider angioma, Poikiloderma of Civatte, inflammatory acne | The candela family of pulse dye laser systems is indicated for the following uses in: general surgery: photocoagulation of benign cutaneous vascular lesion and benign cutaneous lesions. Dermatology/plastic surgery: for treatment of benign cutaneous vascular lesion, such as facial and leg telangiectasia, rosacea, port wine stains, hemangiomas, angioma, spider angioma, poikiloderma of civatte, and benign cutaneous lesions, such as warts, scars, striae and psoriasis, and the treatment of wrinkles. | 1064nm: the tristar laser is intended for the coagulation and hemostasis of benign vascular lesions such as, but not limited to, port wine stains, hemangiomas, warts, telangiectasia, rosacea, venus lake, leg veins, spider veins and poikiloderma of civatte; and treatment of benign cutaneous lesions such as warts, scars, stiae and psoriasis. The laser is also intended for the treatment of benign pigmented lesions such as, but not limited to, lentigos (age sports), solar lentigos (sun spots), café au lait macules, seborrheic keratoses, nevi, chloasma, verrucea, skin tags, keratoses, tattoos (significant reduction in the intensity of black and/or blue/black tattoos) and | Different as the subject device has the addition of the benign pigmented lesion indication which is subject to this 510K |
{7}
510(k) Summary for AdvaTx K250189
| | AdvaTx
(Subject Device) | AdvaTx
K132976
(Predicate Device) | VBeam K043251
(Reference Device) | TriStar K033176
(Reference Device) | Comparison |
| --- | --- | --- | --- | --- | --- |
| | Treatment of Benign Pigmented Lesions.
The ADVATx at 1319nm is indicated for treatment of fine lines and wrinkles. Treatment of atrophic acne scars. Treatment of mild and moderate inflammatory acne vulgaris. | vulgaris, verrucae/ warts, scars, striae, psoriasis.
The ADVATx at 1319nm is indicated for treatment of fine lines and wrinkles. Treatment of atrophic acne scars. Treatment of mild and moderate inflammatory acne vulgaris. | - Treatment of inflammatory acne vulgaris.
- Gynecology: photocoagulation of benign cutaneous lesion and benign vascular lesion in gynecology.
- Podiatry: treatment of benign cutaneous lesions, such as warts.
New indication: treatment of benign epidermal pigmented lesion | plaques.
the later is also indicated for the treatment of wrinkles such as but not limited to, periocular and perioral wrinkles.
additionally, the laser is indicated for the removal of unwanted hair, for the stable long term, or permanent, hair reduction through selective targeting of melanin in hair follicles, and for the treatment of pseudofolliculitis barbae (pfb).
1320nm:
the tristar laser is indicated for use in general surgery and dermatology for the incision, excision, ablation, vaporization, coagulation and hemostasis of soft tissue. It is also indicated for the treatment of periorbital and perioral wrinkles. It is also indicated for the treatment of fine lines and wrinkles. | |
Page 4 of 7
{8}
510(k) Summary for AdvaTx K250189
| | AdvaTx (Subject Device) | AdvaTx K132976 (Predicate Device) | VBeam (Reference Device) | TriStar (Reference Device) | Comparison |
| --- | --- | --- | --- | --- | --- |
| | | | | 585nm: the tristar aesthetic workstation laser is indicated for benign vascular and vascular dependent lesions removal. | |
| Wavelength (nm) | 589 1319 | Same | (595, 532, 755) | 1320 | 589 nm and 595 nm are considered substantially equivalent 1319 nm and 1320 nm are also considered substantially equivalent |
| Spot Size (mm) | 1.0 | Same | 3-12 | 3-10 | Subject device spot size is smaller than those of the predicate device and reference devices. This will not have any additional safety risks as compared to the predicates |
| Pulse Width (ms) | 20-950 @ 589 20-200 @ 1319 | 20-950 @ 589 20-200 @ 1319 | 0.4 - 40 @595 | 0.5-40 | |
| Fluence (J/cm2) | Up to 100 @ 589 Up to 60 @ 1319 | Up to 100 @ 589 Up to 40 @ 1319 | Up to 13.5 @ 595 | Up to 60 @ 1320 | |
| Repetition Rate (Hz) | 0.67 - 1.0 | Same | Max 1.5 | 1-3 | |
{9}
510(k) Summary for AdvaTx K250189
| | AdvaTx
(Subject Device) | AdvaTx
K132976
(Predicate Device) | VBeam
(Reference Device) | TriStar
(Reference Device) | Comparison |
| --- | --- | --- | --- | --- | --- |
| Power Supply | 110-240 V,
50/60 Hz | Same | 200-240 VAC | 200/220 VAC/30A | |
| Dimensions
HxWxD (cm) | 135 x 50 x 62 | Same | unknown | 114 x 50 x 58.5 | |
| Weight (kg) | 63 | Same | 127 | 136 | |
Page 6 of 7
{10}
510(k) Summary for AdvaTx K250189
VI. Performance Testing [21 CFR 807.92(b)(1)]
The following performance data was provided in support of the substantial equivalence determination:
IEC 60601-1 Edition 3.2 2020-08 Test for Medical Electrical equipment was performed for General Requirements for basic safety and essential performance.
IEC 60601-1-2:2014 Test for Medical Equipment for General Requirements for basic safety and essential performance: electromagnetic compatibility
IEC 60601-2-22: 2012 Test for Particular requirements for basic safety and essential performance of surgical, cosmetic, therapeutic and diagnostic laser equipment
ISO 10993-1:2018 Biological Evaluation of Medical Devices - Part 1: Evaluation and Testing Within a Risk Management Process
Software verification and validation testing was conducted and documentation provided as recommended by the FDA's "Guidance for the Content of Premarket Submissions Contained in Medical Devices.
VII. Clinical Data [21 CFR 807.92(b) (2)]
Based on the similarities in the safety and effectiveness profiles of the subject and the predicate, no clinical studies were deemed needed to support this submission.
VIII. Conclusions Safety and Effectiveness SE [21 CFR 807.92(b) (3)]
AdvaTx is as safe and effective as the predicate device. The proposed AdvaTx has the same intended use and indications, same technological characteristics, and same principle of operation as its predicate device. The addition of the higher fluence does not present any new concerns for safety or efficacy. Thus, AdvaTx is substantially equivalent to its predicate.
Page 7 of 7
